[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cholangitis-sclerosing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cholangitis-sclerosing":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100376409","primary-sclerosing-cholangitis-in-children-100376409",false,"NCT04181138","Primary Sclerosing Cholangitis in Children","Prospective Observational Study of Primary Sclerosing Cholangitis (PSC) in Children","Inclusion Criteria:\n\nPatients with the clinical diagnosis of large or small duct PSC made at any time prior to enrollment are screened for eligibility to participate in this prospective cohort study. The site PI will determine eligibility following review of MRCP or ERCP images with the site radiologist to confirm presence of an abnormal cholangiogram at the time of diagnosis of large duct PSC. Liver histopathology obtained at the time of diagnosis of small duct PSC will be reviewed with the site pathologist prior to enrollment.\n\nIndividuals must meet all of the Inclusion criteria in order to be eligible to participate in the study:\n\n1. Aged 2 through 25 years at time of screening.\n2. Diagnosis of large duct PSC based on review of cholangiogram by MRC, ERC, or intraoperative cholangiogram (IOC) by the site radiologist and interpreted to be consistent with PSC, based on one or more of the following:\n\n   * Focal structuring of the bile duct(s)\n   * Dominant stricture of the common bile duct\n   * Saccular dilatation of bile duct(s)\n   * Beaded appearance of bile duct(s)\n   * Pruning appearance of the distal bile duct branches\n\n   AND\u002FOR\n3. Diagnosis of small duct PSC based on review of liver histopathology by the site pathologist and interpreted to be compatible with PSC:\n\n   * Probable small duct PSC: biopsy with ≥3 of 5 criteria: periductal edema, concentric inflammation, bile duct injury, ductular reaction, and neutrophils in bile ducts (cholangitis) OR...\n   * Definitive small duct PSC: Periductal fibrosis\u002F \"onion skinning\" around interlobular bile ducts or smaller profiles\n4. Stated willingness to comply with all study procedures and availability for the duration of the study.\n5. Able to provide informed consent\u002Fassent\n\nParticipants for the imaging study are eligible if they are:\n\n1. Aged 8 through 25 years at the time of screening\n2. No absolute contraindication to MRI\n3. No skin condition that could be aggravated by MREL\n4. Meet all other eligibility criteria of the PSC Observational Study\n5. For whom none of the exclusion criteria apply\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria at baseline will be excluded from participation in this study.\n\n1. History of liver transplantation\n2. History bone marrow transplantation\n3. History of primary or acquired immunodeficiency predisposing to secondary sclerosing cholangitis, for instance: hyper-IgM syndrome, severe combined immunodeficiency (SCID) syndrome, common variable immunodeficiency (CVID) syndrome, cartilage hair hypoplasia syndrome, or HIV\u002FAIDS\n4. History of histiocytosis, including Langerhans cell histiocytosis (LCH), or hemophagocytic lymphohistiocytosis (HLH)\n5. History of ischemic cholangitis\n6. History of portal vein thrombosis with biliopathy, veno-occlusive disease, or abdominal radiation vasculopathy\n7. History of recurrent pyogenic cholangitis\n8. History of biliary tract surgery for cholecystolithiasis prior to cholangiogram\u002Fliver biopsy evaluated to determine enrollment\n9. History of biliary tract surgery for choledochal cyst\n10. History of hepatocellular carcinoma, or hepatoblastoma\n11. History of surgical biliary trauma\n12. History of congenital cytomegalovirus (CMV) hepatitis\n13. History of Sickle Cell Disease\n14. History of cystic fibrosis, biliary atresia, Caroli disease\u002Fcongenital hepatic fibrosis, or progressive familial intrahepatic cholestasis type 3\u002FMDR3 disease\n15. History of cardiac hepatopathy.\n16. History of metabolic disorders, including Wilson's disease, glycogen storage disorder, Alpha-1 Antitrypsin deficiency\n17. Diagnosis of systemic lupus erythematosus (SLE)\n18. Concurrent pregnancy at the time of enrollment -","ALL","2 Years","25 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to the small intestine. Bile is a liquid produced by the liver that helps us absorb and use the nutrients in the food we eat. In people with PSC, the bile backs up into the liver and will damage it, causing scarring of the liver.\n\nThe purposes of this study are to:\n\n* Collect medical and other data to learn more about PSC, how it progresses, and identify factors that may cause the disease to progress more quickly.\n* Ask questions about how PSC symptoms affect your child's life to learn more about its impact on your child's daily functioning\n* Children with PSC who are seen at one of the participating clinical sites in the Childhood Liver Disease Research Network (ChiLDReN) will be asked to contribute information, DNA, and other specimens. The information and specimens will be available to investigators to carry out approved research aimed at learning more about the possible causes and long-term effects of PSC.",[25,26,27],"Primary Sclerosing Cholangitis","Liver Diseases","Cholangitis, Sclerosing",[29,25],"Pediatric Liver Disease","RECRUITING","2026-06-03",{"date":33,"type":34},"2026-06-04","ACTUAL",{"date":36,"type":34},"2021-12-30",{"date":38,"type":21},"2029-05-31",{"name":40,"class":41},"Arbor Research Collaborative for Health","OTHER",12,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":22,"phases":4,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100297049","swiss-primary-sclerosing-cholangitis-cohort-study-100297049","NCT03146936","Swiss Primary Sclerosing Cholangitis Cohort Study","Inclusion Criteria:\n\n* Patients diagnosed with PSC according to established criteria (European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases) of any age. Patients not fulfilling such criteria but still diagnosed with PSC in a hepatology referral centre can be included\n* patients living in Switzerland\n\nExclusion Criteria:\n\n* N\u002FA",{"count":50,"type":21},120,"5 Years","Research project in which biological material is sampled and health-related personal data is further used and collected.\n\nCoded data are used.",[27,54,55],"PSC","Primary Sclerosing Cholangitis (PSC)",[54,25,57],"Cohort","2025-08-14",{"date":60,"type":34},"2025-08-19",{"date":62,"type":34},"2017-02-28",{"date":64,"type":21},"2030-12-31",{"name":66,"class":41},"Fondazione Epatocentro Ticino",21,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":80,"conditions":81,"keywords":85,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100582506","a-simple-breath-test-to-detect-liver-cancer-and-monitor-liver-conditions-100582506","NCT06864195","A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions","Development of a Breath Test Using Volatile Organic Markers for Monitoring Cirrhosis and Detecting Primary Liver Tumours (VOCAL2)","VOCAL2","Inclusion Criteria:\n\n* Males and females\n* Adult participants ≥ 18 years old\n* Participants with either:\n\n  1. Histologically or radiologically-confirmed\\* hepatocellular carcinoma or cholangiocarcinoma (participants with liver cancer)\n  2. Liver cirrhosis, confirmed on imaging or histology from biopsy (participants with benign liver disorders)\n  3. Primary sclerosing cholangitis, confirmed on MRCP\u002FERCP or histology from biopsy (participants with benign liver disorders)\n  4. Non-specific gastrointestinal symptoms, but a radiologically-normal liver (healthy controls)\n\nExclusion Criteria:\n\n* Active infection, or receiving immunosuppressive medications, within the preceding eight weeks\n* History of another cancer within the previous five years\n* Previous liver resection\n* Already received chemotherapy, radiotherapy or surgery for their liver cancer\n* Comorbidities preventing breath collection\n* Pregnant women (checked verbally with participant).\n* Unable to provide informed written consent",true,"18 Years",{"count":79,"type":21},750,"Liver cancer is often diagnosed too late for effective treatment. The VOCAL2 study is developing a simple, non-invasive breath test to help detect liver cancer earlier and monitor liver conditions like cirrhosis. The test analyzes tiny chemicals in exhaled breath called volatile organic compounds (VOCs) to identify signs of liver disease.\n\nWho can take part?\n\nAdults aged 18 or older who:\n\nHave liver cancer (hepatocellular carcinoma or cholangiocarcinoma), or Have liver cirrhosis or primary sclerosing cholangitis, or Have tummy symptoms but a normal liver scan. What's involved?\n\nParticipants will:\n\nGive a breath sample after fasting for 6 hours. Answer a few health questions. Allow access to relevant medical records. The appointment lasts about 1 hour at an NHS hospital. Benefits \\& Risks\n\nThis research could lead to an earlier, easier way to detect liver cancer, but there's no direct health benefit for participants.\n\nThere are no risks, as breath sampling is completely non-invasive and safe. Where is the study happening? Led by Imperial College London, running in NHS hospitals across the UK.\n\nWho is funding the study? The study is funded by Rosetrees and Stoneygate Trust.\n\nContact Information Email: vocal-study@imperial.ac.uk Phone: +44 (0)20 7594 3396",[82,83,84,27],"Liver Cirrhosis","Hepatocellular Carcinoma (HCC)","Cholangiocarcinoma",[86,87,88],"breath","liver cancer","cirrhosis","2025-03-03",{"date":91,"type":34},"2025-03-07",{"date":93,"type":34},"2025-02-13",{"date":95,"type":21},"2027-02-28",{"name":97,"class":41},"Imperial College London",1]